Article ; Online: Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals.
2024
Abstract: Prostate cancer is the most common malignancy in men worldwide, with an estimated 174,650 new cases per year in the United States, and the second cancer-related cause of death, after lung cancer, with 31,620 deaths per year. While the 5 year survival ... ...
Abstract | Prostate cancer is the most common malignancy in men worldwide, with an estimated 174,650 new cases per year in the United States, and the second cancer-related cause of death, after lung cancer, with 31,620 deaths per year. While the 5 year survival rate for prostate cancer in patients without metastatic spread is nearly 100%, those with distant metastases have 5 year survival rates of approximately 30%. Initial diagnosis and assessment are based on PSA levels, Gleason score (derived from prostate biopsy), and advanced imaging modalities, including prostate MR imaging and PSMA-PET/computed tomography in patients with high-risk features. |
---|---|
Language | English |
Publishing date | 2024-04-27 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 2764575-7 |
ISSN | 1879-9809 ; 1556-8598 |
ISSN (online) | 1879-9809 |
ISSN | 1556-8598 |
DOI | 10.1016/j.cpet.2024.03.011 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Einzelsignatur: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.